3 results
Primary:• To compare the overall survival (OS) of patients in the rigosertib group vs the Physician*s Choice group, in all patients and in a subgroup of patients with IPSS-R very high riskSecondary efficacy• To compare rigosertib to Physician*s…
The primary objective of the study is to describe the pharmacokinetics of Nivolumab (how quickly it is absorbed by the body) when injected under the skin (subcutaneously) with or without rHuPH20. rHuPH20 is an enzyme that can increase the absorption…
To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and pertuzumab as maintenance therapy in subjects with advanced HER2+ breast cancer who have had prior treatment with a taxane, trastuzumab, and pertuzumab.